AR030185A1 - Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas - Google Patents
Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicasInfo
- Publication number
- AR030185A1 AR030185A1 ARP010100251A ARP010100251A AR030185A1 AR 030185 A1 AR030185 A1 AR 030185A1 AR P010100251 A ARP010100251 A AR P010100251A AR P010100251 A ARP010100251 A AR P010100251A AR 030185 A1 AR030185 A1 AR 030185A1
- Authority
- AR
- Argentina
- Prior art keywords
- drugs
- diseases
- immunomodulators
- inhibitors
- manufacture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
Abstract
Glutarimidas sustituidas, de la formula (1) en la cual los sustituyentes tienen los significados indicados en la descripcion, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como así también inhibidores de angiopatías y/o enfermedades hematologicas/oncologicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10002509A DE10002509A1 (de) | 2000-01-21 | 2000-01-21 | Substituierte Glutarimide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030185A1 true AR030185A1 (es) | 2003-08-13 |
Family
ID=7628270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100251A AR030185A1 (es) | 2000-01-21 | 2001-01-19 | Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6656937B2 (es) |
| EP (1) | EP1252144B1 (es) |
| JP (1) | JP2003524641A (es) |
| KR (1) | KR20020067614A (es) |
| CN (1) | CN1185215C (es) |
| AR (1) | AR030185A1 (es) |
| AT (1) | ATE451355T1 (es) |
| AU (1) | AU780636B2 (es) |
| BR (1) | BR0108030A (es) |
| CA (1) | CA2398061A1 (es) |
| CO (1) | CO5261626A1 (es) |
| CY (1) | CY1109784T1 (es) |
| DE (2) | DE10002509A1 (es) |
| DK (1) | DK1252144T3 (es) |
| ES (1) | ES2337875T3 (es) |
| HU (1) | HUP0204235A3 (es) |
| IL (1) | IL150813A0 (es) |
| MX (1) | MXPA02007089A (es) |
| NO (1) | NO323395B1 (es) |
| NZ (1) | NZ520759A (es) |
| PE (1) | PE20011067A1 (es) |
| PL (1) | PL356986A1 (es) |
| PT (1) | PT1252144E (es) |
| RU (1) | RU2278857C2 (es) |
| SI (1) | SI1252144T1 (es) |
| SK (1) | SK287173B6 (es) |
| WO (1) | WO2001053261A1 (es) |
| ZA (1) | ZA200206664B (es) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10002509A1 (de) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
| US7842727B2 (en) | 2001-03-27 | 2010-11-30 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| DE10163595A1 (de) | 2001-12-21 | 2003-08-07 | Gruenenthal Gmbh | In 3-Position heterocyclisch substituierte Piperidin-2,6-dione |
| WO2003099760A1 (en) * | 2002-05-22 | 2003-12-04 | Errant Gene Therapeutics, Llc. | Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds |
| EP1511477A4 (en) | 2002-05-22 | 2008-04-09 | Errant Gene Therapeutics Llc | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETO-EPOXYDE COMPOUNDS |
| US20040192738A1 (en) * | 2003-03-18 | 2004-09-30 | Aventis Pharma Deutschland Gmbh | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it |
| ES2374629T3 (es) | 2004-03-17 | 2012-02-20 | Pfizer Products Incorporated | Nuevos derivados de bencil(iden)-lactama. |
| DE102004026703A1 (de) * | 2004-05-28 | 2005-12-29 | Grünenthal GmbH | Verfahren zur Herstellung von in 3-Position heterocyclisch substituierten Piperidin-2,6-dionen |
| WO2014107622A1 (en) | 2013-01-07 | 2014-07-10 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| EP3722290B1 (en) | 2013-04-12 | 2023-06-21 | VALENTA-INTELLEKT Limited | Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative |
| WO2015103489A1 (en) | 2014-01-03 | 2015-07-09 | University Of Southern California | Heteroatom containing deoxyuridine triphosphatase inhibitors |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| US10577321B2 (en) | 2015-07-08 | 2020-03-03 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| DK3319939T3 (da) | 2015-07-08 | 2025-02-24 | Cv6 Therapeutics Ni Ltd | Hydantoin indeholdende deoxyuridintriphosphatase-inhibitorer |
| RU2610275C2 (ru) * | 2015-07-30 | 2017-02-08 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения |
| CN109153644B (zh) * | 2016-03-16 | 2022-10-21 | H·李·莫菲特癌症中心研究有限公司 | 用以增强效应t细胞功能的针对cereblon的小分子 |
| US10829457B2 (en) | 2016-11-23 | 2020-11-10 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| WO2018098209A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
| EP4717317A3 (en) * | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| GEAP202115467A (en) | 2017-09-07 | 2021-10-11 | Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises | Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| CN107903245B (zh) * | 2018-01-15 | 2018-11-13 | 青岛大学附属医院 | 一种化合物及其在制备治疗类风湿性关节炎药物中的应用 |
| CN107857754B (zh) * | 2018-01-15 | 2018-11-09 | 泰山医学院 | 一种化合物及其在制备预防/治疗类风湿性关节炎药物中的应用 |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| EP3820532A4 (en) | 2018-07-11 | 2022-04-06 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | DIMERE IMMUNOMODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR102980990B1 (ko) | 2019-04-05 | 2026-06-25 | 카이메라 쎄라퓨틱스 인코포레이티드 | Stat 분해제 및 이의 용도 |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2021188948A1 (en) | 2020-03-19 | 2021-09-23 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| TN2022000350A1 (en) * | 2020-06-26 | 2024-07-04 | Ltd “Valenta Intellekt” | Use of a glutarimide derivative for treating diseases associated with aberrant interleukin-6 activity |
| US12606568B2 (en) | 2020-12-09 | 2026-04-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその合成 |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2673205A (en) * | 1951-02-13 | 1954-03-23 | Ciba Pharm Prod Inc | 3-disubstituted dioxopiperidines and the manufacture thereof |
| US3214431A (en) * | 1958-08-04 | 1965-10-26 | Pfizer & Co C | Novel glutarimides |
| US5114937A (en) * | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| GB8928043D0 (en) * | 1989-12-12 | 1990-02-14 | Pfizer Ltd | Muscarinic receptor antagonists |
| FR2745811B1 (fr) * | 1996-03-07 | 1998-05-22 | Sanofi Sa | Glutarimide disubstitue procede pour sa preparation, et son utilisation |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| DE19703763C1 (de) * | 1997-02-01 | 1998-10-01 | Gruenenthal Gmbh | Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione |
| DE19843793C2 (de) * | 1998-09-24 | 2000-08-03 | Gruenenthal Gmbh | Substituierte Benzamide |
| DE10002509A1 (de) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
-
2000
- 2000-01-21 DE DE10002509A patent/DE10002509A1/de not_active Ceased
-
2001
- 2001-01-09 KR KR1020027009243A patent/KR20020067614A/ko not_active Ceased
- 2001-01-09 HU HU0204235A patent/HUP0204235A3/hu unknown
- 2001-01-09 PT PT01900400T patent/PT1252144E/pt unknown
- 2001-01-09 SI SI200130961T patent/SI1252144T1/sl unknown
- 2001-01-09 DK DK01900400.1T patent/DK1252144T3/da active
- 2001-01-09 AU AU25140/01A patent/AU780636B2/en not_active Ceased
- 2001-01-09 CA CA002398061A patent/CA2398061A1/en not_active Abandoned
- 2001-01-09 JP JP2001553265A patent/JP2003524641A/ja not_active Withdrawn
- 2001-01-09 MX MXPA02007089A patent/MXPA02007089A/es active IP Right Grant
- 2001-01-09 IL IL15081301A patent/IL150813A0/xx unknown
- 2001-01-09 BR BR0108030-0A patent/BR0108030A/pt not_active IP Right Cessation
- 2001-01-09 PL PL01356986A patent/PL356986A1/xx not_active Application Discontinuation
- 2001-01-09 SK SK1017-2002A patent/SK287173B6/sk not_active IP Right Cessation
- 2001-01-09 EP EP01900400A patent/EP1252144B1/de not_active Expired - Lifetime
- 2001-01-09 NZ NZ520759A patent/NZ520759A/en unknown
- 2001-01-09 RU RU2002121641/04A patent/RU2278857C2/ru not_active IP Right Cessation
- 2001-01-09 ES ES01900400T patent/ES2337875T3/es not_active Expired - Lifetime
- 2001-01-09 CN CNB018038883A patent/CN1185215C/zh not_active Expired - Fee Related
- 2001-01-09 WO PCT/EP2001/000155 patent/WO2001053261A1/de not_active Ceased
- 2001-01-09 DE DE50115252T patent/DE50115252D1/de not_active Expired - Lifetime
- 2001-01-09 AT AT01900400T patent/ATE451355T1/de not_active IP Right Cessation
- 2001-01-19 PE PE2001000061A patent/PE20011067A1/es not_active Application Discontinuation
- 2001-01-19 AR ARP010100251A patent/AR030185A1/es unknown
- 2001-01-19 CO CO01003816A patent/CO5261626A1/es not_active Application Discontinuation
-
2002
- 2002-07-09 NO NO20023319A patent/NO323395B1/no not_active IP Right Cessation
- 2002-07-19 US US10/198,073 patent/US6656937B2/en not_active Expired - Fee Related
- 2002-08-20 ZA ZA200206664A patent/ZA200206664B/en unknown
-
2003
- 2003-09-03 US US10/653,188 patent/US20040048859A1/en not_active Abandoned
-
2010
- 2010-02-11 CY CY20101100143T patent/CY1109784T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28342A1 (es) | Nuevos compuestos | |
| AR028948A1 (es) | Compuestos novedosos | |
| ECSP045410A (es) | Nuevos derivados de piridazin-3(2h)-ona | |
| BR9913745A (pt) | Cetonas de piridina úteis como herbicidas | |
| AR005703A1 (es) | Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen | |
| PA8621501A1 (es) | Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos | |
| GT199900102A (es) | Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen. | |
| PA8595901A1 (es) | "n-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos | |
| UY28348A1 (es) | Compuestos novedosos | |
| UY27729A1 (es) | Inhibidores de quinasas. | |
| ECSP034774A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
| ECSP034773A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
| ECSP066541A (es) | Nuevos derivados de piridazin-3(2h)-ona | |
| UY28946A1 (es) | Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios | |
| TR200102020T2 (tr) | Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler. | |
| HN2002000300A (es) | Nuevos derivados de piperazina | |
| UY27418A1 (es) | Formulaciones en combinación de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilización | |
| ITMI20031570A1 (it) | Composizione per uso dietetico, farmaceutico o cosmetico | |
| BR0108030A (pt) | Glutarimidas substituidas, e seu uso como inibidores de produção de il-12. | |
| AR024138A1 (es) | Inhibidores de la proliferacion celular | |
| PA8575601A1 (es) | Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
| UY27080A1 (es) | Nuevas imidazotriazinonas sustituídas | |
| PA8586801A1 (es) | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso | |
| CR9391A (es) | Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| PA8605101A1 (es) | 4-(aminometil)-piperidin benzamidas como antagonista de 5ht4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |